A recent article in the International Journal of Drug Policy, written by Daniel Ciccarone, attempts to explain the supply and demand drivers of the opioid epidemic in the US.Read More
NanoMedical Systems (NMS), an Austin, Texas based biotechnology firm received a $3mm grant from the US Department of Defense to advance the development of an implantable buprenorphine device. According to an NMS press release:
Indivior's Sublocade is a long-acting (28 days) buprenorphine injection. Unlike Sublocade, the NMS device is expected to be implanted in patients and released for up six months. Such a product could solve some of the problems of other implantable products by releasing a constant flow of medication.
The NMS device is years away, even if it is successful with its clinical trials, but it is exciting to see companies investing in novel treatment methods for opioid use disorder.
The US Food and Drug Administration (FDA) approved a generic version of Suboxone sublingual film, but Indivior, the make of Suboxone, quickly sued to stop generic suppliers from entering the market.Read More